Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome

Rheumatology (United Kingdom)

Volumn 55, Issue 10, 2016, Pages 1726-1735

  Sciascia, Savino ^a   Lopez Pedrera, Chary ^b   Cecchi, Irene ^a   Pecoraro, Clara ^a   Roccatello, Dario ^a,c   Cuadrado, Maria Josè ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c S GIOVANNI BOSCO HOSPITAL   (Italy)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anti phospholipid antibodies; Anti phospholipid syndrome; Apixaban; Dabigatran; Rivaroxaban; Thrombosis

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; LUPUS ANTICOAGULANT; RIVAROXABAN; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; VITAMIN K GROUP;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BREAST FEEDING; FOOD DRUG INTERACTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LABORATORY TEST; LIVER DISEASE; PREGNANCY; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; COMPLICATION; FEMALE; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PREGNANCY COMPLICATIONS; THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBINS; BREAST FEEDING; FACTOR XA INHIBITORS; FEMALE; FOOD-DRUG INTERACTIONS; HEMORRHAGE; HUMANS; KIDNEY DISEASES; LIVER DISEASES; LUPUS COAGULATION INHIBITOR; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS; VITAMIN K;

EID: 84991058634     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev445     Document Type: Review

References (68)

1. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
3. Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e419S-94S.
4. Erkan D, Aguiar CL, Andrade D et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014;13:685-96.
5. Pradaxa 150mg hard capsules. Summary of Product Characteristics (SPC), EU. Boehringer Ingelheim International GmBH, 2012. www.emc.medicines.org.uk (1 September 2015, date last accessed).
6. Xarelto 20mg film-coated tablets. Summary of Product Characteristics (SPC), EU. Bayer HealthCare AG, 2012. www.emc.medicines.org.uk (1 September 2015, date last accessed).
7. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808.
8. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
9. NICE technology appraisal guidance 261. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE, 2012. www.nice.org.uk/TA 261 (1 September 2015, date last accessed).
10. NICE technology appraisal guidance 245. Venous thromboembolism-apixaban (hip and knee surgery). NICE, 2012. www.nice.org.uk/TA (1 September 2015, date last accessed).
11. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
12. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Pradaxa; EMEA/H/C/000829/II/0032. London: European Medicines Agency, 2012. http://www.ema.europa.eu (1 September 2015, date last accessed).
13. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Xarelto; EMEA/H/C/000944/X/0010, 2011. http://www.ema.europa.eu (1 September 2015, date last accessed).
14. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Eliquis; EMA/439534/2014. London: European Medicines Agency, 2014. http://www. ema.europa.eu (1 September 2015, date last accessed).
15. Büller HR, Prins MH, Lensin AWA et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
16. Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol 2015; Advance Access published 30 July 2015, doi: 10.1007/s10067-015-3030-y.
17. Sciascia S, Breen K, Hunt BJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis 2015;26:476-7.
18. Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 2014;89:1017.
19. Bachmeyer C, Elalamy I. Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome. Clin Exp Dermatol 2014;39:840-1.
20. Delgado MG, Rodríguez S, García R et al. Antiphospholipid syndrome of late onset: a difficult diagnosis of a recurrent embolic stroke. J Stroke Cerebrovasc Dis 2015;24:e209-11.
21. Joalland F, de Boysson H, Darnige L et al. [Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report]. Rev Med Interne 2014;35:752-6.
22. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res 2015;135:1035-6.
23. Noel N, Dutasta F, Costedoat-Chalumeau N et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev 2015;14:680-5.
24. Schaefer JK, McBane RD, Black DF et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 2014;112:947-50.
25. ISRCTN Registry. Rivaroxaban in Antiphospholipid Syndrome (RAPS) [trial details]. http://isrctn.org/ISRCTN68222801 (1 September 2015, date last accessed).
26. Cohen H, DoréCJ, Clawson S et al. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus 2015;24:1087-94.
27. Scridon A, Constantin Serban R. Laboratory monitoring-a turning point in the use of new oral anticoagulants. Ther Drug Monit 2015; Advance Access published 3 September 2015, doi: 10.1097/FTD.0000000000000247.
28. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012;159:427-9.
29. Halbmayer W-M, Weigel G, Quehenberger P et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med 2012;50:1601-5.
30. Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem medica 2012;22:329-41.
31. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
32. Lindahl TL, Baghaei F, Blixter IF et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-8.
33. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011;49:761-72.
34. Samama MM, Martinoli J-L, LeFlem L et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
35. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010;85:185-7.
36. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013;11:245-52.
37. Pengo V, Tripodi A, Reber G et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737-40.
38. Keeling D, Baglin T, Tait C et al. Guidelines on oral anticoagulation with warfarin-fourth edition. Br J Haematol 2011;154:311-24.
39. Merriman E, Kaplan Z, Butler J et al. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 2011;105:385-6.
40. van Os GMA, de Laat B, Kamphuisen PW, Meijers JCM, de Groot PG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011;9:1657-9.
41. Martinuzzo ME, Barrera LH, D'adamo MA et al. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol 2014;36:144-50.
42. Arachchillage DRJ, Mackie IJ, Efthymiou M et al. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost 2015;13:1264-73.
43. Góralczyk T, Iwaniec T, Wypasek E, Undas A. Falsepositive lupus anticoagulant in patients receiving rivaroxaban. Blood Coagul Fibrinolysis 2015;26:473-5.
44. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59.
45. Beasley BN, Unger EF, Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011;364:1788-90.
46. Chang M, Yu Z, Shenker A et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2015; Advance Access published 11 September 2015, doi: 10.1002/jcph.633.
47. Eliquis 2.5mg film-coated tablets film-coated tablets. Summary of Product Characteristics (SPC). 2012. www.emc. medicines.org.uk (1 September 2015, date last accessed).
48. Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013;52:243-54.
49. Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 2013;15:331.
50. European Medicines Agency. Xarelto. Summary of Product Characteristics (SPC). 2013. http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/000944/WC500057108.pdf (1 September 2015, date last accessed).
51. European Medicines Agency. Pradaxa. Summary of Product Characteristics (SPC). 2015. http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/000829/WC500041059.pdf (1 September 2015, date last accessed).
52. Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Annu Rev Pharmacol Toxicol 2012;52:79-99.
53. Pengo V, Crippa L, Falanga A et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost 2012;10:1979-87.
54. Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin k antagonists: a systematic review and meta-analysis. PLoS One 2015;10:e0137444.
55. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
56. Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther 2011;9:841-4.
57. Majeed A, Goldhaber SZ, Kakkar A et al. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thromb Haemost 2015;115; Advance Access published 24 September 2015, doi: 10.1160/TH15-04-0319.
58. Franchini M, Bonfanti C, Mannucci PM. Management of bleeding associated with new oral anticoagulants. Semin Thromb Hemost 2015;41:788-801.
59. Breen K, Hunt B. The new oral anticoagulants. Clin Med 2011;11:467-9.
60. Sciascia S, Hunt BJ. New oral anticoagulants in the management of venous thromboembolism: a major advance? Eur J Vasc Endovasc Surg 2014;48:487-8.
61. Levi M, Moore KT, Castillejos CF et al. Comparison of threefactor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014;12:1428-36.
62. Cheung YW, Barco S, Hutten BA et al. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost 2015;13:1799-805.
63. Perzborn E, Heitmeier S, Laux V, Buchmüller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 2014;133:671-81.
64. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 2013;8:e78696.
65. Escolar G, Arellano-Rodrigo E, Lopez-Vilchez I et al. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates-in vitro studies with steady and circulating human blood. Circ J 2015;79:331-8.
66. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9.
67. Pollack CV, Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-20.
68. Costin J, Ansell J, Laulicht B, Bakhru S, Steiner S. Reversal agents in development for the new oral anticoagulants. Postgrad Med 2014;126:19-24.